Injectable Platelet-rich Fibrin Research Articles

Does the application of autologous injectable Platelet-Rich Fibrin (i-PRF) affect the patient’s daily performance during the retraction of upper canines? A single-centre randomized split-mouth controlled trial

BackgroundPrevious studies have assessed different aspects concerning the applications of i-PRF in the oral cavity. However, nothing is known regarding patients’ perceptions of the injection of autologous platelet-rich fibrin (i-PRF).ObjectivesTo investigate patients’ perceptions after injecting platelet-rich fibrin (i-PRF) in the course of retracting upper canines.MethodsTwenty-one patients, whose treatments required extractions of both upper first premolars, were recruited. Extraction side was randomly allocated to the intervention or control sides. After the alignment phase, i-PRF was injected twice with a one-month interval on the buccal and palatal aspects of the extraction sites (intervention side). Patients’ perceptions were evaluated with two questionnaires: the first was used to assess the level of pain, discomfort, swelling, eating and swallowing difficulties as well as jaw movement restriction after 1 h (T1), 2 h (T2), 6 h (T3), 24 h (T4) and 48 h (T5) of the second injection; the second questionnaire was used to assess the acceptance of the i-PRF injection and overall satisfaction with this technique at the end of canine retraction phase. Visual Analogue Scale (VAS) was adopted for this purpose. Wilcoxon Signed Rank Test was used to compare between both sides at all time points while Friedman’s Test was the selected test for detecting variables’ changes over time. Post-hoc Wilcoxon Matched-Pairs Signed-Rank Tests were applied when any of the results were significant. As to the multiplicity of tests, Bonferroni Correction was implemented.ResultsPain and swelling levels were significantly higher on the experimental compared to the control sides at T1, T2, and T3 (P < 0.05), whereas they declined sharply and went back to almost normal values at T4 (after 24 h). At T5 they were 0. Discomfort and difficulty in mastication on intervention sides were significant only at T1 and T2. Pain, swelling, and chewing difficulties were significant (P < 0.001) during the 4 assessed time points. The increase was insignificant regarding swallowing difficulties and jaw movement limitations at all time intervals.ConclusionsInjecting autologous (i-PRF) during orthodontic canine retraction is a well-perceived and well-tolerated method due to the limited discomfort which significantly diminishes 24 h afterwards.Trial’s registrationClinicalTrials.gov (Identifier Number: NCT03399422. 16/01/2018).

Efficiency of hyaluronic acid versus red injectable platelet-rich fibrin (I-PRF) in treatment of stage III periodontitis: Randomized controlled clinical trial

Introduction: This study aims to compare clinical efficacy of red injectable platelet-rich fibrin (i-PRF) and hyaluronic acid (HA) as adjuncts to professional mechanical plaque removal (PMPR) in non-surgical management of stage III periodontitis. Methods: 75 patients were split into groups: group one (G1) received HA, group two (G2) received red i-PRF, and group three (G3), received only PMPR. Periodontal evaluation was done at baseline, 4th, 8th, and 12th weeks following treatment. Results: The plaque index, gingival index, and bleeding on probing were significantly improved in all groups. Moreover, the probing depth in all three groups displayed lower levels over the three months, with G1 and G2 experiencing the greatest declines. Additionally, G1 and G2 showed a considerable increase in clinical attachment level, while G3 showed no improvement. Conclusions: Thus, the application of HA and red i-PRF in conjunction with PMPR significantly improves all periodontal metrics, however, there is no statistically significant distinction between them.

Effect of local administration of injectable platelet-rich fibrin on root resorption during orthodontic tooth movement in dogs

Effect of local administration of injectable platelet-rich fibrin on root resorption during orthodontic tooth movement in dogs

Effect of local injection of injectable platelet-rich fibrin on bone remodeling during orthodontic tooth movement in dogs

Effect of local injection of injectable platelet-rich fibrin on bone remodeling during orthodontic tooth movement in dogs

Autologous tooth bone graft block compared with advanced platelet-rich fibrin in alveolar ridge preservation: A clinico-radiographic study.

To determine the clinico-radiographic efficiency of partially demineralized dentin matrix block (PDDM block), a mixture of PDDM with advanced-platelet-rich fibrin+ (A-PRF+) and injectable platelet-rich fibrin versus A-PRF+ alone in alveolar socket preservation. Sixteen molar teeth indicated for extraction were randomly assigned into two groups. For the test group, sockets were packed with PDDM block and control group, with A-PRF+ plug alone. Clinical and radiographic cone-beam computed tomography methods were used to assess the horizontal and vertical ridge dimensional changes at baseline and 4 months. Clinically, the mid buccal and palatal crestal height (10.25 ± 0.86 and 9.75 ± 0.28 mm) and alveolar ridge width (11.37 ± 0.25 mm) were significantly higher in the test group as compared to the control group, 4 months after tooth extraction (P < 0.01). Radiographically, there was improved apposition and nonsignificant resorption for the test group in ridge height and width, whereas statistically significant higher resorption was seen in the control group at 4 months. The application of the PDDM block demonstrated efficacy in maintaining the dimensions of the extraction socket when compared to A-PRF+ alone. This autologous and immune-free regenerative biomaterial is widely obtainable, offering a glimpse into the potential of next-generation biofuels for regeneration.

Injectable platelet rich fibrin versus hyaluronic acid with bovine derived xenograft for alveolar ridge preservation. A randomized controlled clinical trial with histomorphometric analysis.

Alveolar ridge preservation (ARP) is a technique that aims to maintain bone volume and minimize resorption after tooth extraction. This study aimed to compare the effectiveness of injectable platelet-rich fibrin (I-PRF) versus hyaluronic acid (HA) in combination with xenografts for ARP. This randomized controlled trial included 36 patients (20 females and 16 males) who required implant placement in the upper arch. The patients were randomly allocated to one of three groups (n = 12 each): I-PRF with xenografts, HA with xenografts, or xenografts alone. All patients underwent ARP, and the extraction sockets were sealed with a free gingival graft harvested from the palate, a total of 36 implants were inserted. Cone-beam CT scans were performed before and 4 months postoperatively to measure radiographic bone gain as the primary outcome. Clinical parameters, including soft tissue thickness and clinical bone width, were evaluated preoperatively, and at 4 months and 1 year postoperatively. Additionally, histological assessment of core bone biopsies was performed 4 months postoperatively using histomorphometric analysis to determine the percentages of newly formed bone, mature bone, and residual grafts. Regarding the radiographic bone gain 4 months postoperative the HA group exhibited the highest value (9.78 ± 0.87), which was significantly greater than the values observed in the I-PRF and control groups (8.60 ± 1.27 and 7.99 ± 0.89, respectively) (one-way ANOVA, p = 0.007). Crestal bone loss was significantly higher in the control group (-0.98 ± 0.18) than in the I-PRF group (-0.53 ± 0.11) and HA group (-0.33 ± 0.15) groups (one-way ANOVA, p < 0.001). In the histomorphometric analysis, the mean area fraction of newly formed bone trabeculae was significantly higher in the HA group (56.66 ± 7.35) than in the I-PRF group (28.74 ± 5.15) and the control group (24.05 ± 3.64) (repeated measures ANOVA, p < 0.001). Additionally, the mean area fraction of residual graft material was higher in the I-PRF group (6.76 ± 2.59), followed by the control group (2.71 ± 1.24), while the HA group had the lowest value (2.63 ± 1.27) (Repeated measures ANOVA, p < 0.001). The combination of HA with xenografts yielded better radiographic and histological outcomes in terms of new bone formation and degree of bone maturation than the I-PRF and control groups. Furthermore, I-PRF improved soft tissue thickness. Please note that clinical trial registration was not completed prior to participant recruitment and randomization. The registration link for this trial is https://clinicaltrials.gov/ct2/show/NCT05781529.

Evaluation of Socket Preservation Using Collagen Plug and Injectable Platelet Rich Fibrin in Extracted Sockets of Mandibular Molars: A Split Mouth Study

Aim and Objectives: Evaluation of socket preservation using collagen plug and injectable platelet rich fibrin in extracted sockets of mandibular molars. To evaluate wound healing and bone density using collagen plug and I-PRF and to compare wound healing and bone density between collagen plug and I-PRF. Methodology: This experimental study involves 13 healthy patients at the Sibar Institute of Dental Sciences and Hospital in Guntur, Andhra Pradesh, India, who underwent mandibular molar extraction under local anesthesia. Patients underwent clinical and radio-graphic examinations and received periodontal treatment. The study involved extraction of right and left mandibular molar teeth, AbGel placement, collagen plug placement, and sockets secured with sutures and pressure packs. Postoperative pain, swelling, and wound healing were assessed using Wong-Baker faces pain rating scale, VAS scale, and LANDRY healing index. CBCT was obtained after 1 month and 3 months after extraction for bone quality assessment. Results: In the study, there were 69.2% men and 30.8% women. According to the study, 14.3% of individuals in the collagen plug group and 85.7% of those who received injectable platelet-rich fibrin experienced very good wound healing. On the first and seventh days, the mean pain intensity was lower in the injectable group, but there was not a noticeable distinction between the groups. The injectable group had the lowest swelling score, but by day seven, it had dramatically decreased. At the third month, the collagen plug group had the highest bone density readings, with no discernible difference between the groups. Conclusion: It can be concluded that I-PRF can be utilized as an alternative to collagen plug.

Innovative i-PRF semisurgical method for gingival augmentation and root coverage in thin periodontal phenotypes: a preliminary study.

The aim of the study was to evaluate the effect of injectable platelet-rich fibrin (i-PRF) on gingival thickness and gingival recession in individuals with thin periodontal phenotypes. In this prospective study, i-PRF was applied via a semisurgical method to augment 53 tooth regions with thin periodontal phenotypes. In order to ensure that sufficient blood clot formed on the side of the gingiva facing the bone and that i-PRF reached the area, a minimal incision was made with the help of a scalpel in the apical region of the relevant region, and the periosteum was elevated with a microsurgical instrument. To ensure sustained exposure to angiogenetic growth factors and enhance the histoconductive properties, i-PRF injection was applied to the relevant areas in four sessions at 10-day intervals. An increase in gingival thickness was achieved in 92.5% of the areas treated with i-PRF, and the desired gingival thickness (0.8 mm) was achieved in 44.9% of these areas. In addition, significant reductions in the amount of recession were observed in 83.3% of the 12 gingival recession areas (P = .005). Moreover, complete coverage was achieved in 60% of these regions. With the new i-PRF semisurgical method, it was shown that gingival thickness can be increased in tooth regions with thin gingiva, and that areas of gingival recession can be covered. Further comprehensive studies are needed to fully understand the role of i-PRF in enhancing angiogenesis and the histoconductive properties of this fully autogenous blood concentrate.

The Effects of Injectable Platelet-Rich Fibrin and Advanced-Platelet Rich Fibrin on Gingival Fibroblast Cell Vitality, Proliferation, Differentiation.

Injectable Platelet Rich Fibrin (I-PRF) and Advanced-Platelet Rich Fibrin (A-PRF) are autologous materials derived from patients' blood and employed in periodontal regenerative surgery. Although I-PRF and A-PRF have different characteristics, their biological effects on gingival tissue fibroblasts remain unclear. This research aims to compare the in vitro capacity in inducing gene expression and proliferation of human gingival fibroblasts between A-PRF and I-PRF. Human donors undergoing dental implant surgery were sampled for normal human gingival fibroblasts (NHGFCs), followed by preparing A-PRF and I-PRF membranes. Enzyme-linked immunosorbent assay (ELISA) kit was used to assess the release of platelet-derived growth factor-AA (PDGF-AA), transforming growth factor-beta1 (TGF- β1), and insulin growth factor-1 (IGF-1) at different periods. Cell viability and proliferation of A-PRF and I-PRF were compared using CCK-8 assay. The impacts of platelet concentration on human gingival fibroblast cells (HGFCs) were evaluated by quantifying the level or amount of phosphorylated extracellular signal-regulated protein kinase (p-ERK), and Matrix metalloproteinases (MMPs), MMP-1 and MMP-3. The effects of PRF on aged human gingival fibroblast cells were examined retrospectively. Overall, A-PRF demonstrated a higher release of TGF-B1 and PDGF-AA, while I-PRF reflected higher levels of IGF-1. A significantly higher level of cell proliferation was induced by higher cell proliferation by A-PRF and I-PRF. Additionally, in comparison to I-PRF, the expression of ERK phosphorylation and MMP-1 &MMP-3 in HGFCs was demonstrated by I-PRF and A-PRF. The increase in A-PRF was time-dependent (p < 0.05). Both I-PRF and A-PRF induced a stimulatory biological impact on the proliferation of human gingiva fibroblasts, with the latter demonstrating better capacity in facilitating the release of different growth factors. A-PRF also induced higher gene expression of p-ERK, MMP-1 &MMP-3, and the proliferation of fibroblasts.

Use of Injectable Platelet-Rich Fibrin Accompanied by Bone Graft in Socket Endurance: A Radiographic and Histological Study.

Background Ridge preservation became a crucial dental health issue and strategy to keep away from ridge defacement after post-tooth loss. The recent scientific evolution of platelet-rich fibrin (PRF) comprises a parenteral formulation of PRF. The combined allograft for socket preservation gives benefits. In this study, bone allografts, demineralized freeze-dried bone allografts (DFDBA) and freeze-dried bone allografts (FDBA) are used in a 30:70 ratio alone or in combination with injectable PRF (I-PRF) for socket preservation. Methods This study is a radiographic and histological examination conducted on 60 participants aged between 19-65 years. Participating patients agreed voluntarily that theywould not bear any fixed prosthesis for the next nine months and plan for implantedteethplacement, including multi-rooted mandibular molars denticles. Both groups received atraumatic extraction; then, the socket was preserved with bone allograft alone in the control group and bone allograft mixed with I-PRF, forming sticky bone, in the experimental group. Clinical, radiological, and histological assessments were taken at the inception stage, three months, six months, and nine months. A multivariate regression model and a generalized estimating equation (GEE) model were used to analyse the effects of these changes on outcomes. Results In all the parameters, the test group indicated a good amount of bone growth with increasing intervals of time for bone height radiographically with statistically significant difference present (p<0.05) and histologically after nine months when socket site grafted with bone graft in combination with I-PRF. Conclusion This study's results demonstrated thatI-PRF possesses the potential to regenerate and healin the tooth-extracted socket. This study further recommends the implementation of I-PRF in safeguarding and conserving the raised rim of the tooth. Future research should take place on the osteogenic capability of I-PRF in more comprehensive ridge accession surgical procedures and additional expanding and improving capacities in periodontal reconstruction.

Treatment with injectable platelet-rich fibrin in a rat model of melasma.

The management of melasma is challenging. Platelet-rich plasma (PRP) therapy has been shown to be beneficial, however, the use of anticoagulants for PRP is dangerous. To evaluate the efficacy of recently developed blood-derived biomaterials (injectable platelet-rich fibrin [I-PRF]) in a rat model of melasma. Sprague Dawley (SD) rats were used to replicate an experimental animal model of melasma. SD rats exhibiting melasma were randomly divided into experimental and control groups. The experimental group was administered weekly intradermal injections of I-PRF, whereas the control group received an equivalent amount of saline. After four weeks, back skin was removed and evaluated based on (1) gross observation, (2) pathological examination and imaging analysis, and (3) biochemical detection. Data were analysed using SAS9.4 software. I-PRF, a safe blood product without anticoagulants, inhibited melanin production in the epidermis and reduced oxidative stress damage in the cortex, improving melasma. I-PRF is a safe and cost-effective blood-derived biomaterial which is useful for the treatment of melasma.

Evaluation of platelet derived growth factor-BB levels in injectable platelet rich fibrin coated graft using gingival pedicle split thickness tunnel technique for isolated gingival recession: A randomized controlled trial

BackgroundUse of injectable-platelet rich fibrin (i-PRF) in the field of periodontal regeneration is quite well known due to its efficacy. The study was aimed to evaluate the platelet derived growth factor-BB (PDGF-BB) levels in cases of isolated gingival recession using gingival pedicle split thickness tunnel technique (GPST) and de-epithelialized gingival graft (DGG) with or without coating it with i-PRF. Methodology20 patients exhibiting Miller’s class I/II isolated gingival recession were selected for this parallel arm randomized controlled trial. Recipient site was prepared using GPST technique, free gingival graft was harvested and de-epithelialized, further graft was coated with i-PRF and wound fluid samples from surgical site were collected at baseline, 3rd day and 7th day for group A. The same procedure without coating the graft in i-PRF was carried out for group B. Clinical parameters like probing depth, recession depth, recession width, width of keratinized gingiva, wound healing index (WHI), complete root coverage was recorded at baseline and after 4 months. ResultsSignificant intergroup difference was seen in WHI and the levels of PDGF-BB from baseline to the last estimated time point (p < 0.05). ConclusionThe study emphasizes on the use of novel GPST technique in conjunction with DGG coated with liquid PRF, which has shown sustained release of PDGF-BB resulting in better wound healing.

Comparison of Antimicrobial Activity of Injectable Platelet-Rich Fibrin (i-PRF) and Leukocyte and Platelet-Rich Fibrin (l-PRF) Against Oral Microbes: An In Vitro Study.

Aim Injectable platelet-rich fibrin (i-PRF) and leukocyte and platelet-rich fibrin (l-PRF) are both blood-derived products used in regenerative medicine and dentistry. They contain platelets, growth factors, and leukocytes, which can have antimicrobial properties to some extent, but their primary purpose is tissue regeneration and wound healing. i-PRF and l-PRF may have some indirect antimicrobial properties due to their composition and ability to enhance tissue healing and immune responses, and they are primarily used in dentistry for their regenerative and wound healing capabilities rather than as standalone antimicrobial agents. This study aims to compare the anti-microbial activity of i-PRF and l-PRF against oral microbes. Methodology This study included 30 patients who were selected using G*Power software version 3.1 (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany) calculation with the population size. The plaque samples were collected from the subjects using area-specific Gracey curettes used for scaling and root planing to remove plaque and calculus from the teeth and root surfaces. The collected plaque samples were transferred to a tube containing 5 ml of saline (sterile saltwater). The purpose of using saline is to preserve the microbial content of the plaque sample without altering the microbial composition. To obtain a uniform solution, the samples in the saline-containing tube were vortexed for 5 minutes. After vertexing, a small amount of the suspension (0.1 ml) was taken for further analysis. The 0.1 ml suspension was used to plate blood agar using the streak method. A loop or needle is used to streak the sample back and forth across the surface of the agar, leading to the dilution and separation of the bacteria. Results Results state that i-PRF has a maximum zone of inhibition (2.19±0.47 mm) when compared with metronidazole (0.14±0.09 mm). It can be stated that platelet concentrates demonstrate better antimicrobial activity due to their higher oxygen metabolites which help in the aggregation and internalization of microorganisms, which enhances the clearance of pathogens from the bloodstream. Paired t-test has been used for the comparison between the two groups, and the p-value is >0.05 stating that the difference is statistically significant. Conclusion The present study states that i-PRF demonstrated better antimicrobial efficacy as compared to l-PRF. Hence, i-PRF helps in reducing microbial load at the periodontally infected sites when compared with l-PRF.

Is Injectable Platelet-Rich Fibrin Really Effective in Reducing Expected Side Effects of Removing Impacted Third Molar Surgery?

Common side effects of third molar (M3) operations including pain, edema, and trismus have an adverse effect on patient quality of life. Injectable platelet-rich fibrin (i-PRF) may ameliorate some of the side effects of the operation. The primary purpose of this study is to measure and compare differences in pain, swelling, trismus, and quality of life between i-PRF side and a control side of subjects undergoing M3 removal. This study is a single-center, split-mouth, randomized prospective clinical trial conducted at Ordu University Faculty of Dentistry. Patients who presented between March and August 2022 for the extraction of impacted third molars due to various reasons were included in the study. The exclusion criteria were local conditions and systematic comorbidities. Additionally, patients with differences that could cause bias between the sides were excluded from the study. The predictor variable is treatment i-PRF or control. The outcome variables of interest are the pain level and analgesic consumption values on the Visual Analog Scale, the distance between determined reference points, maximum mouth opening, and the Postoperative Symptom Severity scale data. A Postoperative Symptom Severity scale was created using questions commonly employed in the clinical evaluation of patients following the extraction of third molars. This scale was further divided into subscales corresponding to the 7 primary adverse effects identified in a prior study. Covariate variables, sex, age, and operation times. The normality of the distribution of the study data was assessed using the Kolmogorov-Smirnov test. Depending on whether the data exhibited a normal distribution or not, the data were analyzed using either the paired t-test or the Wilcoxon test. A P value < .05 was considered statistically significant. The study included 35 patients with a mean age of 19.97±2.07years. The i-PRF side significant success in postoperative edema measurements. There was a statistically significant difference observed between the control side and the i-PRF side on the second day (control: 9.74±0.57mm, i-PRF: 9.46±0.51mm) and seventh day (control: 9.33±0.59mm, i-PRF: 9.12±0.50mm) in lateral canthus-angulus measurements (P: .01 and P: .04, respectively). Additionally, on the second day, there was a statistically significant difference in tragus-commisura measurements (control: 11.53±0.62mm, i-PRF: 11.31±0.58mm) with a P value of .02. There was no significant difference observed between the sides in terms of postoperative pain (P>.05). However, analgesic consumption in the i-PRF side was significantly lower at the sixth hour (control: 1.8±0.58 dose, i-PRF: 1.14±0.35 dose), 24th hour (control: 1.77±0.54 dose, i-PRF: 1.14±0.35 dose), and second day (control: 1.8±0.47 dose, i-PRF: 1.4±0.73 dose) postoperatively (P: .000, P: .000, and P: .012). Mouth opening was significantly lower in the i-PRF side on the second day (control: 27.88±6.48mm, i-PRF: 25.51±5.56mm) (P: .025). However, i-PRF had no significant effect on postoperative quality of life (P>.05). According to the study results, i-PRF had a limited effect on the management of postoperative pain, but i-PRF was effective in reducing postoperative edema. Further studies with larger patient sides are now needed to yield more detailed findings on the subject.

Clinical evaluation of the combined efficacy of injectable platelet-rich fibrin along with scaling and root planing in the non-surgical periodontal therapy of stage III and grade C periodontitis patients having type 2 diabetes mellitus: Arandomized controlled trial.

This randomized controlled trial was aimed to evaluate the combined efficacy of injectable platelet-rich fibrin (i-PRF) and scaling and root planing (SRP) in type 2 diabetes mellitus subjects having periodontitis. Twenty-six Stage III, grade C periodontitis subjects (HbA1c > 7) were recruited in this split-mouth study. Following SRP, the test sites received subgingival application of i-PRF, while the control sites received saline. Plaque index, bleeding on probing, modified gingival index, probing pocket depth (PPD) and clinical attachment level (CAL) were measured at baseline, 3 and 6 months. Twenty-three participants completed the course of research. The Friedman test followed by Dunn's post hoc test, revealed significant improvement in all the clinical parameters from baseline to 3 and 6 months in both the study groups (p ≤ 0.05). The mean PPD and CAL decreased from 6.30 ± 1.25 and 7.48 ± 1.75 at baseline to 3.48 ± 1.34 and 4.39 ± 1.67 at 6 months in control sites and from 6.57 ± 1.56 and 7.61 ± 1.69 to 3.39 ± 1.23 and 4.26 ± 1.81 at 6 months in test sites (p ≤ 0.0001). Intergroup analysis found no statistical significant differences in the evaluated parameters across all time intervals (p > 0.05) CONCLUSION: The results indicated that the adjunctive application of i-PRF to SRP provided similar benefits as saline and SRP in diabetes mellitus subjects. Question: To find the combined efficacy of injectable platelet-rich fibrin (i-PRF) along with scaling and root planing (SRP) in the management of periodontal pockets of Stage III and Grade C periodontitis patients having Type 2 Diabetes Mellitus (T2DM). All of the treated sites showed satisfactory healing. Both the treatment modalities (i-PRF + SRP and Saline + SRP) were effective in the treatment of periodontal pockets. At 3 and 6 months, there were no significant differences in periodontal parameters between groups. Meaning: The application of i-PRF as an adjunct to SRP provided similar benefits as saline and SRP in improving clinical parameters in subjects with stage III and grade C periodontitis patients having T2DM (HbA1C > 7).

Antimicrobial effect of platelet-rich fibrin: A systematic review of in vitro evidence-based studies.

This systematic review (SR) aimed to evaluate the antimicrobial potential of different types of platelet-rich fibrin (PRF) often used in regenerative treatments. An electronic search was performed in four databases and in Gray literature for articles published until January, 2023. The eligibility criteria comprised in vitro studies that evaluated the antimicrobial effect of different types of PRF. For the analysis of the risk of bias within studies, the modified OHAT (Office of Health Assessment and Translation) tool was used. For the evaluation of the results, a qualitative critical analysis was carried out in the synthesis of the results of the primary studies. Sixteen studies published between 2013 and 2021 were included in this SR. The antimicrobial effects of PRF variations (PRF, injectable PRF [I-PRF], PRF with silver nanoparticles [agNP-PRF], and horizontal PRF [H-PRF]), were analyzed against 16 types of bacteria from the oral, periodontal, and endodontic environments. All types of PRF showed significant antimicrobial action, with the antibacterial efficacy being more expressive than the fungal one. The I-PRF, H-PRF, and agNP-PRF subtypes improve antimicrobial activity. According to the OHAT analysis, no study was classified as having a high risk of bias. Evidence suggests that PRF variations have significant antimicrobial activity, with bacterial action being greater than fungal. Evolutions such as I-PRF, H-PRF, and agNP-PRF improve antimicrobial activity. Future studies analyzing the clinical effect of these platelets are fundamental. This SR was registered in INPLASY under number INPLASY202340016.

Impact of Biphasic Calcium Phosphate mixed with injectable platelet rich fibrin (i-PRF) on bone density in surgically created bone defects in a sheep animal model (A Radiographic Assessment)

Impact of Biphasic Calcium Phosphate mixed with injectable platelet rich fibrin (i-PRF) on bone density in surgically created bone defects in a sheep animal model (A Radiographic Assessment)

Assessment of Biphasic Calcium Phosphate mixed with injectable platelet rich fibrin (i-PRF) on healing of surgically created bone defects in a sheep animal model (A Histological Analysis)

Assessment of Biphasic Calcium Phosphate mixed with injectable platelet rich fibrin (i-PRF) on healing of surgically created bone defects in a sheep animal model (A Histological Analysis)

CLINICAL APPLICATIONS OF INJECTABLE PLATELET RICH FIBRIN (IPRF) IN ADJUVANT THERAPY FOR PERIODONTITIS: A CASE SERIES

The purpose of this study is to evaluate the clinical outcomes of non-surgical periodontal therapy using injectable Platelet Rich Fibrin (iPRF). Materials and Methods: In the present study, analyzed the results of treatment in 82(43 men and 39 women, aged 36 to 63 years) patients in the period from 2018 to 2023 years with periodontitis stages I–II were included. The following clinical parameters were recorded at the beginning of the study (before and treatment), after 1 month (after iPRF therapy), at the end of the 3-month (after iPRF therapy). The diagnosis of periodontitis was established taking radiological signs of bone loss and indicators of bleeding on probing (BOP), probing depth (PD), Clinical attachment level (CAL). All patients subjected to the complex periodontal treatment included supragingival and subgingival scaling and root debridement with an ultrasonic device, antibacterial therapy. After 4 weeks, only those patients underwent I-PRF therapy who maintained optimal oral hygiene. I PRF was injected into the gum area. The number of plasma-based sessions is strictly individual and depends on the severity of the inflammatory process (4-6 sessions break between sessions 1 week). Results: The postoperative periods in all patients passed without complications, there were no serious intraoperative or immediate postoperative complications. After a course of I-PRF therapy, patients noted elimination of pain, bleeding and swelling of the gums, tooth mobility became less bad breath disappeared, loss of bone tissue stopped. The first changes in the gums are noticeable on the 7th-10th day. The clinical picture and diagnostic parameters were comparable at baseline and after treatment. The clinical periodontal parameters (BOP, PPD, CAL) were shown a reduction in their mean values after 3 months from the treatment with the PRP, with a highly significant difference no complications had been observed. The mean value BOP before treatment was 2.6 ± 0.32, after 1month treatment the mean BOP 1.8 ± 0.2, after 3 months treatment the mean BOP 1.4 ± 0.15. The mean value PPD before treatment was 5.41 ± 0.77 mm, 1 month after therapy it was 4,27 ±0.38 mm and 3 month after therapy it was 2.46 ± 0.42 mm. The mean value CAL before treatment was 5.84 ± 0.79 mm, 1 month after therapy it was was 4.92 ± 0.71 mm. and 3 months after therapy it was 3,4 ± 0,7 mm. Conclusion: This study confirmed that iPRF periodontal therapy can be successfully used in patients diagnosed with I-II periodontitis who have received individualization supportive periodontal therapy and regular periodontal maintenance. The use of iPRF in periodontal therapy represents a valuable minimally invasive adjunct to complex conservative therapy.

Angiogenesis-promoting composite TPMS bone tissue engineering scaffold for mandibular defect regeneration

Mandibular defects severely impact the patient&amp;rsquo;s quality of life and are difficult problems to treat in the clinical setting. Due to the limitations of current gold-standard therapies, there is a tremendous need for tissue engineering approaches to meet this rising clinical demand. Injectable platelet-rich fibrin (I-PRF) containing a variety of pro-regenerative growth factors and stromal cell-derived factor-1 (SDF-1) has been shown to be beneficial in stimulating angiogenesis. In this study, we developed a three-cycle minimally curved biomimetic bone tissue engineering scaffold made of &amp;beta;-tricalcium phosphate, modified with I-PRF and SDF-1. I-PRF was loaded at a concentration of 5% onto a triply periodic minimal surface (TPMS) scaffold with a porosity of 70%. CCK-8 experiments and live-dead staining confirmed the scaffold&amp;rsquo;s good biocompatibility and its ability to promote cell proliferation. Wound healing assays showed that the TPMS scaffold loaded with I-PRF and SDF-1 (SIT) enhanced cell migration of MC3T3 cells. Moreover, angiogenesis experiments showed that the SIT scaffold promoted angiogenesis. Importantly, alkaline phosphatase and alizarin red staining confirmed that the bone scaffold accelerated MC3T3 cells&amp;rsquo; osteogenic differentiation and mineralization. The SIT bone scaffold was then implanted into a rabbit mandible defect model. After a 2-month post-implantation period, micro- CT analysis revealed the growth of new bone tissue around the SIT construct, while histological analysis which included hematoxylin-eosin (H&amp;E) staining and masson&amp;rsquo;s trichrome staining, alkaline phosphatase (ALP) staining, osteoprotegerin (OPG) staining demonstrated that the SIT scaffold substantially promoted the growth of a highly vascularized fibrous and bone tissue in the defect site. Taken together, these findings demonstrate the considerable potential of TPMS scaffolds loaded with I-PRF and SDF-1 in promoting the repair of mandible defects.